Form 4: Biotech Growth N.V. Sells 5,784,292 Shares of Black Diamond Therapeutics

Biotech Growth N.V., a 10% owner of Black Diamond Therapeutics, Inc., disposed of 5,784,292 shares of common stock on March 19, 2025.

Summary

• Biotech Growth N.V. sold 5,784,292 shares of Black Diamond Therapeutics, Inc. (BDTX) common stock on March 19, 2025.
• The sales were executed at various prices ranging from $1.943 to $2.3081 per share.
• Following these transactions, Biotech Growth N.V. directly owns 2,733,547 shares of BDTX.
• BB Biotech AG, the parent company of Biotech Growth N.V., may be deemed the indirect beneficial owner of these securities.
• The Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the large sale of shares by a major shareholder, which could indicate a lack of confidence in the company's future prospects or a need for the shareholder to liquidate their position.

Negatives

• Biotech Growth N.V., a significant shareholder, reduced its stake in Black Diamond Therapeutics by selling a substantial number of shares.

Risks

• The sale of a large number of shares by a major shareholder like Biotech Growth N.V. could potentially exert downward pressure on the stock price of Black Diamond Therapeutics.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell shares. These filings are closely watched by investors for insights into the perspectives of those with the most knowledge of the company.

Stakeholder Impact

• Shareholders may react negatively to the news of a large share sale by a major shareholder.
• The sale could potentially impact employee morale if perceived as a lack of confidence in the company's future.

Key Dates

Keywords

Black Diamond Therapeutics, Biotech Growth N.V., BB Biotech AG, Form 4, share sale, beneficial ownership, BDTX